What’s driving biopharma markets in Q1 2026?
The first quarter delivered a strong set of signals.
Capital remains available, but deployment is more measured. Investors and acquirers are prioritizing assets with clear differentiation, credible data and defined paths to value, while external uncertainty continues to influence timing and appetite.
This report explores how those forces are playing out across M&A, public markets, venture funding and mid cap performance.
A late quarter surge lifted M&A volumes and values to recent highs, supported by strong balance sheets, looming patent cliffs and sustained interest in mid sized and China linked assets.
The report will help you to:
- Track the latest biopharma M&A, IPO and venture funding activity
- Understand how investor and acquirer priorities are shifting
- Benchmark current market conditions against recent quarters
- Inform strategic, portfolio and investment decisions with trusted data
Read the full report for a clear, data driven view of where biopharma stands after the first quarter of 2026.
